Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608585 | 0.91 | STK17A (0.45) | STK17ASTK17B | |
| SCHEMBL3609399 | 0.87 | SIRT5 (0.49) | STK17ASTK17B | |
| SCHEMBL3608858 | 0.85 | AXL (0.41) | STK17ASTK17B | |
| SCHEMBL3603990 | 0.82 | CAMK2D (0.60) | STK17ASTK17B | |
| SCHEMBL3603530 | 0.81 | CSNK2A1 (0.62) | STK17ASTK17B | |
| SCHEMBL3616045 | 0.81 | SYK (0.52) | — | |
| SCHEMBL3610465 | 0.81 | CAMK2D (0.60) | STK17ASTK17B | |
| SCHEMBL13503001 | 0.77 | STK17A (0.48) | STK17ASTK17B | |
| SCHEMBL3602192 | 0.77 | CAMK2D (0.58) | STK17ASTK17B | |
| SCHEMBL3612180 | 0.76 | CAMK2D (0.69) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | EISAI CO. LTD. | 2010-04-15 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | STK17A 1726/4885STK17B 1950/4885 |
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | STK17A 4710/4885STK17B 4591/4885 |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | STK17A 1726/4885STK17B 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.